Seattle Times OpEd: Ebola Needs a New Model of Drug Development
Jennifer Dent, president of BVGH, contributed an OpEd to the Seattle Times in August outlining the need for new approaches to drug development for diseases important in the developing world, such as Ebola. The recent outbreak of Ebola is West Africa has been declared an international public health emergency by the World Health Organization. Read the full article.
Four New WIPO Re:Search Collaborations Finalized in May
Four new collaborations were finalized under WIPO Re:Search in May, including one between Eisai and the Liverpool School of Tropical Medicine (LSTM). Under this agreement, Eisai will provide a set of inhibitors to the LSTM to examine inflammation induced by Plasmodium-infected red blood cell adherence to vascular endothelial cells. To learn about the other new collaborations, read the latest WIPO Re:Search Snapshot.
Merck Fellows Joined BVGH for the Summer
Katherine Young and Nicole Buist, research scientists at Merck, completed their fellowships with BVGH in August. After two weeks with the BVGH team in Seattle, Katherine and Nicole weree hosted by research institutions in Cameroon, Ghana and Kenya. Learn more about BVGH’s Fellowship Programs.
BVGH Hosted Panel Sessions at the 2014 BIO International Convention
Jennifer Dent, president of BVGH, hosted two panel sessions at the Biotechnology Industry Organization’s (BIO) annual International Convention on June 25th in San Diego: The Changing Landscape of Industry’s Engagement in Global Health and Africa: The Next Biotech Frontier?.